Header Logo

Connection

FASIHA KANWAL to Antiviral Agents

Back to Details
This is a "connection" page, showing publications FASIHA KANWAL has written about Antiviral Agents.
FASIHA KANWAL
Connection Strength
9.002
Antiviral Agents
  1. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.448
  2. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019 07; 50(1):66-74.
    View in: PubMed
    Score: 0.440
  3. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
    View in: PubMed
    Score: 0.438
  4. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019 06; 156(8):2149-2157.
    View in: PubMed
    Score: 0.435
  5. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.414
  6. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.393
  7. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.385
  8. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
    View in: PubMed
    Score: 0.382
  9. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016 11; 64(5):1442-1450.
    View in: PubMed
    Score: 0.358
  10. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis. 2016 08 01; 63(3):291-9.
    View in: PubMed
    Score: 0.356
  11. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol. 2015 Oct 01; 15:124.
    View in: PubMed
    Score: 0.342
  12. Why We Should Be Willing to Pay for Hepatitis C Treatment. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1711-3.
    View in: PubMed
    Score: 0.335
  13. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1381-3.
    View in: PubMed
    Score: 0.307
  14. The end of hepatitis C. Clin Gastroenterol Hepatol. 2014 Apr; 12(4):533-6.
    View in: PubMed
    Score: 0.305
  15. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci. 2014 Feb; 59(2):273-81.
    View in: PubMed
    Score: 0.295
  16. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
    View in: PubMed
    Score: 0.274
  17. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012 Jan 01; 54(1):96-104.
    View in: PubMed
    Score: 0.263
  18. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006 Sep; 101(9):2076-89.
    View in: PubMed
    Score: 0.182
  19. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005 May 17; 142(10):821-31.
    View in: PubMed
    Score: 0.167
  20. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
    View in: PubMed
    Score: 0.164
  21. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.138
  22. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.133
  23. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020 11 02; 3(11):e2021173.
    View in: PubMed
    Score: 0.122
  24. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
    View in: PubMed
    Score: 0.115
  25. The HCV Treatment Cascade: Race Is a Factor to Consider. J Gen Intern Med. 2019 10; 34(10):1949-1951.
    View in: PubMed
    Score: 0.113
  26. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019 06 11; 9(6):e026726.
    View in: PubMed
    Score: 0.110
  27. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.109
  28. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019 03; 17(4):739-747.e8.
    View in: PubMed
    Score: 0.105
  29. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018 06; 67(6):2085-2095.
    View in: PubMed
    Score: 0.102
  30. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther. 2018 Apr; 47(7):1023-1031.
    View in: PubMed
    Score: 0.101
  31. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):115-122.e10.
    View in: PubMed
    Score: 0.096
  32. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017 03; 65(3):777-788.
    View in: PubMed
    Score: 0.093
  33. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):122-132.
    View in: PubMed
    Score: 0.093
  34. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015 Mar 17; 162(6):397-406.
    View in: PubMed
    Score: 0.082
  35. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.079
  36. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):327-333.e1.
    View in: PubMed
    Score: 0.074
  37. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
    View in: PubMed
    Score: 0.073
  38. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology. 2013 Mar; 144(3):478-81.
    View in: PubMed
    Score: 0.072
  39. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012 Oct; 107(10):1512-21.
    View in: PubMed
    Score: 0.068
  40. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011 Mar; 53(3):737-45.
    View in: PubMed
    Score: 0.062
  41. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
    View in: PubMed
    Score: 0.061
  42. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med. 2010 Aug 17; 153(4):231-9.
    View in: PubMed
    Score: 0.060
  43. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clin Gastroenterol Hepatol. 2024 01; 22(1):91-101.e6.
    View in: PubMed
    Score: 0.036
  44. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023 02 18; 76(4):592-599.
    View in: PubMed
    Score: 0.036
  45. Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Ann Hepatol. 2023 Mar-Apr; 28(2):100899.
    View in: PubMed
    Score: 0.035
  46. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.035
  47. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clin Gastroenterol Hepatol. 2023 05; 21(5):1362-1364.e1.
    View in: PubMed
    Score: 0.034
  48. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.033
  49. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol. 2022 07; 77(1):55-62.
    View in: PubMed
    Score: 0.033
  50. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012 Feb; 56(2):320-5.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.